Information for MS patients interested in stem cell therapy at The Ottawa Hospital
January 28, 2015
Stem cell therapy holds promise for the treatment of multiple sclerosis (MS), but it can be difficult for patients to find reliable information about the types of therapies available, their possible benefits and risks, and how to access these therapies. This page is meant to help people understand the two kinds of stem cell therapies available for MS at The Ottawa Hospital.
If you think you may be eligible for one of these treatments, you should discuss the possibility with your neurologist and ask for a referral to The Ottawa Hospitalís MS Clinic (if you are not already a patient here).
To understand these therapies, it is important to note that MS is an autoimmune disease that develops sometime after birth, when the bodyís immune system mistakenly attacks the brain and spinal cord. One of the therapies available at The Ottawa Hospital (called Immunoablation and Autologous Hematopoietic Stem Cell Transplantation) works by completely eliminating the bodyís defective immune system and replacing it with a new healthy one derived from the bodyís own bone marrow-derived hematopoietic stem cells. The other therapy being offered (Mesenchymal Stem Cell Therapy) is still experimental, but the hope is that it will reduce the immune systemís attack on the body and help repair nerve tissue.
Mesenchymal Stem Cell Therapy
Immunoablation and Autologous Hematopoietic Stem Cell Transplantation
Who can access this therapy?
|This therapy is experimental, and is only available through participation in the MESCAMS clinical trial. |
This trial can only accept patients (aged 18 to 50) with relapsing-remitting MS in whom at least one of the existing therapies has not thoroughly contained disease activity, as well as those with secondary and primary progressive forms of MS that continue to have active disease activity.
For detailed inclusion and exclusion criteria, see trial NCT02239393 at ClinicalTrials.gov. (See "How can I participate?", below)
|This therapy is used only for patients with aggressive (but still early) forms of MS in whom existing therapies have not thoroughly contained disease activity.|
The Ottawa Hospital has performed a clinical trial of this treatment (summarized at ClinicalTrials.gov in trial NCT01099930), which has now been completed.
This treatment is currently available for appropriate patients. (See "How can I participate?", below)
What type of stem cell is used and how do these cells work?
|This procedure uses Mesenchymal Stem Cells, which are also called Mesenchymal Stromal Cells or MSCs. These cells can be found in adult bone marrow, fat and skin tissue, as well as umbilical cord blood. Although they can give rise to other cell types, their therapeutic potential seems to come more from their ability to modify the immune system (i.e. reduce inflammation) and release factors that help prevent and repair tissue damage.||This procedure uses very high doses of chemotherapy and antibodies to eliminate the defective immune system. A new immune system is regenerated from Hematopoietic Stem Cells, or HSCs. These cells can be found in adult bone marrow and blood, as well as umbilical cord blood, and they can give rise to all of the cells that make up the blood and immune system. The new immune system no longer attacks the brain and spinal cord.|
What does the procedure involve?
|MSCs are extracted from the patientís own bone marrow and expanded over several weeks in a specialized culture laboratory. The MSCs are maintained frozen, and later thawed, then infused back into the same patient, intravenously.||The first step is to obtain the cells capable of replacing the defective immune system. Using chemotherapy and a stimulating drug, the patientís own HSCs are mobilized from the bone marrow into the bloodstream where they are extracted and purified in a specialized laboratory and then frozen. The patient then receives strong chemotherapy to completely eliminate their existing, defective immune system. Then they receive an intravenous infusion of their previously frozen HSCs, which expand in the body to give rise to a new immune system that no longer attacks the brain and spinal cord. This is a complex treatment with significant side effects (patients should discuss this in detail with their neurologist).|
Where else is this procedure available?
|This procedure is also available at Health Sciences Centre Winnipeg through the same MESCAMS trial. The international arm of this trial (called MESEMS) is also accepting patients in Europe and elsewhere. Patients can search for other clinical trials at ClinicalTrials.gov. |
Note that CloserLookatStemCells.org provides a list of signs to look for and questions to ask when researching stem cell therapies.
|Other specialized bone marrow transplant centres may offer this procedure. Patients should consult with their own neurologist for more information.|
Are there any residency requirements?
|The MESCAMS trial at The Ottawa Hospital will only accept residents of Canada with valid health insurance (OHIP or equivalent). |
Participants from outside Ottawa will be requested to relocate to the area for the duration of the trial (approximately one year).
|Patients must have valid Canadian health insurance (OHIP or equivalent). Patients must reside close to Ottawa for a time, and then must reside close to a major health-care facility familiar in the monitoring required following this type of treatment.|
How can I participate?
|The first step is to discuss this option with your own neurologist. If your neurologist, after reviewing the inclusion and exclusion criteria (available at ClinicalTrials.gov Ė trial NCT02239393), believes that you might be a good candidate for this procedure, he or she can send a referral to The Ottawa Hospital MS Clinic for consideration.||The first step is to discuss this with your own neurologist. If your neurologist believes that you might be a good candidate for this procedure, he or she can send a referral to The Ottawa Hospital MS Clinic for consideration.|
- Frequently asked questions about clinical research
- Media release announcing funding for MESCAMS
- Multiple Sclerosis Society of Canada (major funder of this research)
- ClinicalTrials.gov page for MESCAMS (NCT02239393)
- ClinicalTrials.gov page for completed trial of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation for MS (NCT01099930)
- A Closer Look at Stem Cell Treatments (includes questions to that patients should ask)
About the Ottawa Hospital Research Institute
The Ottawa Hospital Research Institute is the research arm of The Ottawa Hospital and is an affiliated institute of the University of Ottawa, closely associated with its faculties of Medicine and Health Sciences. The Ottawa Hospital Research Institute includes more than 1,700 scientists, clinical investigators, graduate students, postdoctoral fellows and staff conducting research to improve the understanding, prevention, diagnosis and treatment of human disease. Support our research. Give to the Tender Loving Research campaign.